Am J Transplant, Volume 19, Suppl 3 Archives - Page 29 of 214 - ATC Abstracts

2019 American Transplant Congress
Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody)
S. Ge¹, A. Petrosyan¹, M. Chu¹, N. Ammerman², A. Vo², S. C. Jordan², X. Zhang³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ³HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: IL-6 is a pro-inflammatory cytokine involved in KTx rejection. A clinical trial to improve cABMR using CLZ in HLA-sensitized KTx Pts is underway. Inhibition…
2019 American Transplant Congress
Natural Killer Cells Express Significantly More CD16 during Chronic Active Antibody Mediated Rejection Which is Not Caused by a Single Nucleotide Polymorphism within the CD16 Gene
K. Sablik, N. Litjens, A. Peeters, M. Clahsen-van Groningen, M. Klepper, M. Betjes
Erasmus MC, Rotterdam, Netherlands
*Purpose: Chronic-active antibody mediated rejection (c-aABMR) is the leading cause of long-term renal allograft loss. Fc-receptor CD16 bearing natural killer (NK) cells may be involved…
2019 American Transplant Congress
Management of Inactive Candidates on the Kidney Transplant Waitlist: Results from a National Survey
J. Hiller, J. Chen, K. Covarrubias, K. Jackson, J. Long, S. DiBrito, D. Segev, J. Garonzik Wang
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: As the inactive deceased donor kidney transplant (DDKT) waitlist pool continues to grow, management of these patients has become an increasingly complex administrative undertaking.…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…
2019 American Transplant Congress
Effect of Everolimus on IgM and IgG Memory B Cell Growth and Survival In Vitro and Applications for Effective Administration in Clinical Practice
Y. Matsuda
Osaka University Graduate School of Medicine, Osaka, Japan
*Purpose: Everolimus (EVR), which is converted from CNI, is reported to improve renal function and reduce renal toxicity, DSA production, and rejection development. However, there…
2019 American Transplant Congress
A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
T. A. Horwedel¹, C. E. Carthon¹, S. E. January¹, A. Gharabagi¹, R. Delos Santos², J. C. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ²Nephrology, Washington University School of Medicine, Saint Louis, MO
*Purpose: Beginning in December 2015, our center instituted a protocol change moving to de novo use of LCPT. The objective of this study is to…
2019 American Transplant Congress
Optimizing Opportunity and Benefits of Steroid Avoidance in the New KAS Era
S. Sultan, M. Aull, R. Friedlander, V. K. Sharma, D. Serur, A. Watkins, S. Kapur, D. Dadhania
New York Presbyterian / Weill Cornell, New York, NY
*Purpose: The introduction of the new Kidney Allocation System (KAS) in 2014 has facilitated transplantation of sensitized patients with high CPRA. However, the CPRA value…
2019 American Transplant Congress
Staged Procedure In Simultaneous Liver And Kidney Transplant -the “Swedish” Experience
A. Gravetz
Transplant Surgery, Swedish Medical Center, Seattle, WA
*Purpose: As many as 30% of liver transplant candidates have renal insufficiency requiring a combined liver and kidney transplantation. The prolonged and complex simultaneous liver-kidney…
2019 American Transplant Congress
Statin Underutilization in Patients Listed for Liver Transplant
K. Mishra¹, S. Naffouj¹, S. Modi¹, C. Dagher¹, S. Gorgis¹, D. Venkat²
¹Internal Medicine, Henry Ford Hospital, Detroit, MI, ²Transplant Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Current guidelines recommend statin use in high risk patients based on the ASCVD (atherosclerotic cardiovascular disease) score, diabetes, or LDL levels. Despite several trials…
2019 American Transplant Congress
Letermovir for CMV Treatment in Solid Organ Transplant
O. Witkowsky, M. Chunduru, A. Chung, A. Diez
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Letermovir (LET), a novel anti-CMV agent, was recently approved for CMV prophylaxis in stem cell transplant recipients and is currently under investigation as a…